Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

(2020) Olaf Penack et al.   Lancet Haematology

Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression

(2019) Lucas P. Wachsmuth et al.   JOURNAL OF CLINICAL INVESTIGATION

Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation

(2019) Giorgia Battipaglia et al.   BLOOD

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation

(2019) Arnon Nagler et al.   LEUKEMIA

Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors

(2018) Ana Sofia Jorge et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

(2018) Raynier Devillier et al.   BONE MARROW TRANSPLANTATION

Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on

(2018) Yishai Ofran et al.   BRITISH JOURNAL OF HAEMATOLOGY

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

(2018) Annalisa Ruggeri et al.   Journal of Hematology & Oncology

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

(2017) Robert J. Soiffer et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial

(2017) Jürgen Finke et al.   Lancet Haematology

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

(2016) M. Mielcarek et al.   BLOOD

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

(2016) Irwin Walker et al.   LANCET ONCOLOGY

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice

(2014) S. Ganguly et al.   BLOOD

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation

(2014) F Baron et al.   BONE MARROW TRANSPLANTATION

A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors

(2013) Mats Remberger et al.   CLINICAL TRANSPLANTATION

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

(2013) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide

(2013) C. G. Kanakry et al.   Science Translational Medicine

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases

(2012) Roberto Crocchiolo et al.   CANCER

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

(2011) R. J. Soiffer et al.   BLOOD

Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation

(2011) John R. Wingard et al.   JOURNAL OF CLINICAL ONCOLOGY

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

(2011) Z Peric et al.   LEUKEMIA

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

(2010) L. Luznik et al.   BLOOD

Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation

(2010) Paul J. Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION